Recent News

• 11.06.2026 - Off-the-shelf DLL3/CD70 dual CAR T cells with optimized site-specific integration for SCLC and neuroendocrine tumors
• 11.05.2026 - Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
• 11.05.2026 - Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
• 11.04.2026 - ALLO-329: Autoimmune Disease Program Update from ACR Convergence
• 11.03.2026 - Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
• 11.03.2026 - Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
• 11.03.2026 - The Allogene Therapeutics Third Quarter 2026 Conference Call
• 10.29.2026 - Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
• 10.29.2026 - Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
• 10.26.2026 - Jefferies Global Healthcare Conference

Recent Filings

• 11.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2026 - 8-K Current report
• 11.05.2026 - EX-99.1 EX-99.1
• 10.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.21.2026 - 144 Report of proposed sale of securities
• 09.30.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 09.02.2026 - 8-K Current report
• 08.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.21.2026 - 144 Report of proposed sale of securities